Darapladib (BioDeep_00000177961)
human metabolite blood metabolite
代谢物信息卡片
N-[2-(Diethylamino)ethyl]-2-(2-{[(4-fluorophenyl)methyl]sulphanyl}-4-oxo-1H,4H,5H,6H,7H-cyclopenta[D]pyrimidin-1-yl)-N-{[4-(trifluoromethyl)-[1,1-biphenyl]-4-yl]methyl}acetamide
化学式: C36H38F4N4O2S (666.2651456)
中文名称: 达普拉缔
谱图信息:
最多检出来源 Homo sapiens(blood) 71.43%
分子结构信息
SMILES: CCN(CC)CCN(CC1=CC=C(C=C1)C1=CC=C(C=C1)C(F)(F)F)C(=O)CN1C2=C(CCC2)C(=O)N=C1SCC1=CC=C(F)C=C1
InChI: InChI=1S/C36H38F4N4O2S/c1-3-42(4-2)20-21-43(22-25-8-12-27(13-9-25)28-14-16-29(17-15-28)36(38,39)40)33(45)23-44-32-7-5-6-31(32)34(46)41-35(44)47-24-26-10-18-30(37)19-11-26/h8-19H,3-7,20-24H2,1-2H3
描述信息
C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent
D004791 - Enzyme Inhibitors > D064801 - Phospholipase A2 Inhibitors
Darapladib (SB-480848) is an orally active, selective and reversible Lp-PLA2 inhibitor (IC50=0.25 nM). Darapladib can trigger irreversible actions on glioma cell apoptosis and induce cycle arrest. Darapladib can be used in the study of atherosclerosis and cancer[1][2][3][4].
同义名列表
4 个代谢物同义名
N-[2-(Diethylamino)ethyl]-2-(2-{[(4-fluorophenyl)methyl]sulphanyl}-4-oxo-1H,4H,5H,6H,7H-cyclopenta[D]pyrimidin-1-yl)-N-{[4-(trifluoromethyl)-[1,1-biphenyl]-4-yl]methyl}acetamide; N-[2-(diethylamino)ethyl]-2-(2-{[(4-fluorophenyl)methyl]sulfanyl}-4-oxo-1H,4H,5H,6H,7H-cyclopenta[d]pyrimidin-1-yl)-N-{[4-(trifluoromethyl)-[1,1-biphenyl]-4-yl]methyl}acetamide; Darapladib; SB-480848
数据库引用编号
8 个数据库交叉引用编号
- PubChem: 9939609
- HMDB: HMDB0250867
- DrugBank: DB06311
- ChEMBL: CHEMBL204021
- Wikipedia: Darapladib
- chemspider: 8115230
- CAS: 356057-34-6
- medchemexpress: HY-10521
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Mihee Oh, Seo Young Jang, Ji-Yoon Lee, Jong Woo Kim, Youngae Jung, Jiwoo Kim, Jinho Seo, Tae-Su Han, Eunji Jang, Hye Young Son, Dain Kim, Min Wook Kim, Jin-Sung Park, Kwon-Ho Song, Kyoung-Jin Oh, Won Kon Kim, Kwang-Hee Bae, Yong-Min Huh, Soon Ha Kim, Doyoun Kim, Baek-Soo Han, Sang Chul Lee, Geum-Sook Hwang, Eun-Woo Lee. The lipoprotein-associated phospholipase A2 inhibitor Darapladib sensitises cancer cells to ferroptosis by remodelling lipid metabolism.
Nature communications.
2023 09; 14(1):5728. doi:
10.1038/s41467-023-41462-9. [PMID: 37714840] - Matthias Paulus Wagner, Pauline Formaglio, Olivier Gorgette, Jerzy Michal Dziekan, Christèle Huon, Isabell Berneburg, Stefan Rahlfs, Jean-Christophe Barale, Sheldon I Feinstein, Aron B Fisher, Didier Ménard, Zbynek Bozdech, Rogerio Amino, Lhousseine Touqui, Chetan E Chitnis. Human peroxiredoxin 6 is essential for malaria parasites and provides a host-based drug target.
Cell reports.
2022 06; 39(11):110923. doi:
10.1016/j.celrep.2022.110923. [PMID: 35705035] - Gorav Batra, Tatevik Ghukasyan Lakic, Johan Lindbäck, Claes Held, Harvey D White, Ralph A H Stewart, Wolfgang Koenig, Christopher P Cannon, Andrzej Budaj, Emil Hagström, Agneta Siegbahn, Lars Wallentin. Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome.
JAMA cardiology.
2021 12; 6(12):1440-1445. doi:
10.1001/jamacardio.2021.3079. [PMID: 34431970] - Pauline Morigny, Doris Kaltenecker, Julia Zuber, Juliano Machado, Lisa Mehr, Foivos-Filippos Tsokanos, Hanna Kuzi, Chris D Hermann, Michael Voelkl, German Monogarov, Christoph Springfeld, Victor Laurent, Bernd Engelmann, Helmut Friess, Inka Zörnig, Achim Krüger, Jeroen Krijgsveld, Olga Prokopchuk, Søren Fisker Schmidt, Maria Rohm, Stephan Herzig, Mauricio Berriel Diaz. Association of circulating PLA2G7 levels with cancer cachexia and assessment of darapladib as a therapy.
Journal of cachexia, sarcopenia and muscle.
2021 10; 12(5):1333-1351. doi:
10.1002/jcsm.12758. [PMID: 34427055] - Qing Li, Chunlei Feng, Lingyun Li, Guiliang Xu, Haijuan Gu, Shiqiang Li, Dali Li, Mingyao Liu, Shuhua Han, Biao Zheng. Lipid Receptor G2A-Mediated Signal Pathway Plays a Critical Role in Inflammatory Response by Promoting Classical Macrophage Activation.
Journal of immunology (Baltimore, Md. : 1950).
2021 05; 206(10):2338-2352. doi:
10.4049/jimmunol.2000231. [PMID: 33941654] - Shaoqiu Zhuo, Chong Yuan. Active site competition is the mechanism for the inhibition of lipoprotein-associated phospholipase A2 by detergent micelles or lipoproteins and for the efficacy reduction of darapladib.
Scientific reports.
2020 10; 10(1):17232. doi:
10.1038/s41598-020-74236-0. [PMID: 33057060] - Titin Andri Wihastuti, Fitria Nugraha Aini, Cholid Tri Tjahjono, Yuni Hendrati Sulfia, Zuhrotus Sholichah, Teuku Heriansyah. Lp-PLA2 Selective Inhibitor (Darapladib) Effect In Lowering The Expression Level Of IL-1B And IL-6 In The Renal At Type 2 Diabetes Mellitus.
Vascular health and risk management.
2019; 15(?):503-508. doi:
10.2147/vhrm.s217904. [PMID: 31802883] - Guo-Hua Wang, Jun Jin, Li-Zhou Sun. Effect of lipoprotein-associated phospholipase A2 inhibitor on insulin resistance in streptozotocin-induced diabetic pregnant rats.
Endocrine journal.
2018 Sep; 65(9):903-913. doi:
10.1507/endocrj.ej17-0351. [PMID: 29925744] - Brian A Bergmark, Jacob A Udell, David A Morrow, Christopher P Cannon, Dylan L Steen, Petr Jarolim, Andrzej Budaj, Christian Hamm, Jianping Guo, KyungAh Im, Julia F Kuder, Eugene Braunwald, Marc S Sabatine, Michelle L O'Donoghue. Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial.
JAMA cardiology.
2018 06; 3(6):473-480. doi:
10.1001/jamacardio.2018.0653. [PMID: 29710336] - Titin Andri Wihastuti, Teuku Heriansyah, Hanifa Hanifa, Sri Andarini, Zuhrotus Sholichah, Yuni Hendrati Sulfia, Aditya Angela Adam, Jeki Refialdinata, Nurul Cholifah Lutfiana. Darapladib inhibits atherosclerosis development in type 2 diabetes mellitus Sprague-Dawley rat model.
Endocrine regulations.
2018 Apr; 52(2):69-75. doi:
10.2478/enr-2018-0008. [PMID: 29715185] - Woong Gil Choi, Megha Prasad, Ryan Lennon, Rajiv Gulati, Abhiram Prasad, Lilach O Lerman, Amir Lerman. Long-term darapladib use does not affect coronary plaque composition assessed using multimodality intravascular imaging modalities: a randomized-controlled study.
Coronary artery disease.
2018 03; 29(2):104-113. doi:
10.1097/mca.0000000000000573. [PMID: 29135482] - Teuku Heriansyah, Nafisa Nafisatuzzamrudah, Fitria N Aini, Muhammad Ridwan, Rozah F Primardhika, Maya Wijayanti, Rachmad S Bekti, Titin A Wihastuti. Reduction in Vasa Vasorum Angiogenesis by Lp-PLA2 Selective Inhibitor Through The HIF-1α and VEGF Expression Under Dyslipidemic Conditions in Atherosclerosis Pathogenesis.
Cardiovascular & hematological agents in medicinal chemistry.
2018; 16(2):114-119. doi:
10.2174/1871525716666181105151429. [PMID: 30394217] - Claes Held, Harvey D White, Ralph A H Stewart, Andrzej Budaj, Christopher P Cannon, Judith S Hochman, Wolfgang Koenig, Agneta Siegbahn, Philippe Gabriel Steg, Joseph Soffer, W Douglas Weaver, Ollie Östlund, Lars Wallentin. Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial.
Journal of the American Heart Association.
2017 Oct; 6(10):. doi:
10.1161/jaha.116.005077. [PMID: 29066452] - Nimish K Acharya, Xin Qi, Eric L Goldwaser, George A Godsey, Hao Wu, Mary C Kosciuk, Theresa A Freeman, Colin H Macphee, Robert L Wilensky, Venkat Venkataraman, Robert G Nagele. Retinal pathology is associated with increased blood-retina barrier permeability in a diabetic and hypercholesterolaemic pig model: Beneficial effects of the LpPLA2 inhibitor Darapladib.
Diabetes & vascular disease research.
2017 05; 14(3):200-213. doi:
10.1177/1479164116683149. [PMID: 28301218] - Lars Wallentin, Claes Held, Paul W Armstrong, Christopher P Cannon, Richard Y Davies, Christopher B Granger, Emil Hagström, Robert A Harrington, Judith S Hochman, Wolfgang Koenig, Sue Krug-Gourley, Emile R Mohler, Agneta Siegbahn, Elizabeth Tarka, Philippe Gabriel Steg, Ralph A H Stewart, Robert Weiss, Ollie Östlund, Harvey D White. Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease.
Journal of the American Heart Association.
2016 06; 5(6):. doi:
10.1161/jaha.116.003407. [PMID: 27329448] - Mindy He Magee, Bonnie Shaddinger, David Collins, Shabana Siddiqi, Joseph Soffer. The pharmacokinetics and safety of darapladib in subjects with severe renal impairment.
British journal of clinical pharmacology.
2015 Oct; 80(4):654-61. doi:
10.1111/bcp.12661. [PMID: 25953363] - Chaoying Hu, Debra Tompson, Mindy Magee, Qian Chen, Yan Mei Liu, Wenjing Zhu, Hongxin Zhao, Annette S Gross, Yun Liu. Single and Multiple Dose Pharmacokinetics, Pharmacodynamics and Safety of the Novel Lipoprotein-Associated Phospholipase A2 Enzyme Inhibitor Darapladib in Healthy Chinese Subjects: An Open Label Phase-1 Clinical Trial.
PloS one.
2015; 10(10):e0139862. doi:
10.1371/journal.pone.0139862. [PMID: 26465780] - Mindy He Magee, Shawn Shearn, Bonnie Shaddinger, Zixing Fang, Ruchira Glaser. An effect of moderate hepatic impairment on the pharmacokinetics and safety of darapladib.
British journal of clinical pharmacology.
2014 Nov; 78(5):1014-21. doi:
10.1111/bcp.12436. [PMID: 24938621] - Harvey D White, Claes Held, Ralph Stewart, Elizabeth Tarka, Rebekkah Brown, Richard Y Davies, Andrzej Budaj, Robert A Harrington, P Gabriel Steg, Diego Ardissino, Paul W Armstrong, Alvaro Avezum, Philip E Aylward, Alfonso Bryce, Hong Chen, Ming-Fong Chen, Ramon Corbalan, Anthony J Dalby, Nicolas Danchin, Robbert J De Winter, Stefan Denchev, Rafael Diaz, Moses Elisaf, Marcus D Flather, Assen R Goudev, Christopher B Granger, Liliana Grinfeld, Judith S Hochman, Steen Husted, Hyo-Soo Kim, Wolfgang Koenig, Ales Linhart, Eva Lonn, José López-Sendón, Athanasios J Manolis, Emile R Mohler, José C Nicolau, Prem Pais, Alexander Parkhomenko, Terje R Pedersen, Daniel Pella, Marco A Ramos-Corrales, Mikhail Ruda, Mátyás Sereg, Saulat Siddique, Peter Sinnaeve, Peter Smith, Piyamitr Sritara, Henk P Swart, Rody G Sy, Tamio Teramoto, Hung-Fat Tse, David Watson, W Douglas Weaver, Robert Weiss, Margus Viigimaa, Dragos Vinereanu, Junren Zhu, Christopher P Cannon, Lars Wallentin. Darapladib for preventing ischemic events in stable coronary heart disease.
The New England journal of medicine.
2014 May; 370(18):1702-11. doi:
10.1056/nejmoa1315878. [PMID: 24678955] - Mehul Dave, Mike Nash, Graeme C Young, Harma Ellens, Mindy H Magee, Andrew D Roberts, Maxine A Taylor, Robert W Greenhill, Gary W Boyle. Disposition and metabolism of darapladib, a lipoprotein-associated phospholipase A2 inhibitor, in humans.
Drug metabolism and disposition: the biological fate of chemicals.
2014 Mar; 42(3):415-30. doi:
10.1124/dmd.113.054486. [PMID: 24378325] - Joel L Johnson, Yi Shi, Rose Snipes, Salim Janmohamed, Timothy E Rolfe, Bill Davis, Anthony Postle, Colin H Macphee. Effect of darapladib treatment on endarterectomy carotid plaque lipoprotein-associated phospholipase A2 activity: a randomized, controlled trial.
PloS one.
2014; 9(2):e89034. doi:
10.1371/journal.pone.0089034. [PMID: 24586490] - Martin Koch, Michael Wiese. Gene expression signatures of angiocidin and darapladib treatment connect to therapy options in cervical cancer.
Journal of cancer research and clinical oncology.
2013 Feb; 139(2):259-67. doi:
10.1007/s00432-012-1317-9. [PMID: 23052694] - Hui Zhang, Jin-Ying Zhang, Tong-Wen Sun, De-Liang Shen, Fei He, Yu-Hua Dang, Ling Li. Amelioration of atherosclerosis in apolipoprotein E-deficient mice by inhibition of lipoprotein-associated phospholipase A2.
Clinical and investigative medicine. Medecine clinique et experimentale.
2013 Feb; 36(1):E32-41. doi:
10.25011/cim.v36i1.19403. [PMID: 23374598] - Hiroyuki Daida, Takayuki Iwase, Shigeru Yagi, Hidekazu Ando, Hiromu Nakajima. Effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity in Japanese dyslipidemic patients, with exploratory analysis of a PLA2G7 gene polymorphism of Val279Phe.
Circulation journal : official journal of the Japanese Circulation Society.
2013; 77(6):1518-25. doi:
10.1253/circj.cj-12-0813. [PMID: 23439604] - Robert S Rosenson, Diana M Stafforini. Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2.
Journal of lipid research.
2012 Sep; 53(9):1767-82. doi:
10.1194/jlr.r024190. [PMID: 22665167] - Nadeem Sarwar, Adam S Butterworth, Daniel F Freitag, John Gregson, Peter Willeit, Donal N Gorman, Pei Gao, Danish Saleheen, Augusto Rendon, Christopher P Nelson, Peter S Braund, Alistair S Hall, Daniel I Chasman, Anne Tybjærg-Hansen, John C Chambers, Emelia J Benjamin, Paul W Franks, Robert Clarke, Arthur A M Wilde, Mieke D Trip, Maristella Steri, Jacqueline C M Witteman, Lu Qi, C Ellen van der Schoot, Ulf de Faire, Jeanette Erdmann, Heather M Stringham, Wolfgang Koenig, Daniel J Rader, David Melzer, David Reich, Bruce M Psaty, Marcus E Kleber, Demosthenes B Panagiotakos, Johann Willeit, Patrik Wennberg, Mark Woodward, Svetlana Adamovic, Eric B Rimm, Tom W Meade, Richard F Gillum, Jonathan A Shaffer, Albert Hofman, Altan Onat, Johan Sundström, Sylvia Wassertheil-Smoller, Dan Mellström, John Gallacher, Mary Cushman, Russell P Tracy, Jussi Kauhanen, Magnus Karlsson, Jukka T Salonen, Lars Wilhelmsen, Philippe Amouyel, Bernard Cantin, Lyle G Best, Yoav Ben-Shlomo, JoAnn E Manson, George Davey-Smith, Paul I W de Bakker, Christopher J O'Donnell, James F Wilson, Anthony G Wilson, Themistocles L Assimes, John-Olov Jansson, Claes Ohlsson, Åsa Tivesten, Östen Ljunggren, Muredach P Reilly, Anders Hamsten, Erik Ingelsson, Francois Cambien, Joseph Hung, G Neil Thomas, Michael Boehnke, Heribert Schunkert, Folkert W Asselbergs, John J P Kastelein, Vilmundur Gudnason, Veikko Salomaa, Tamara B Harris, Jaspal S Kooner, Kristine H Allin, Børge G Nordestgaard, Jemma C Hopewell, Alison H Goodall, Paul M Ridker, Hilma Hólm, Hugh Watkins, Willem H Ouwehand, Nilesh J Samani, Stephen Kaptoge, Emanuele Di Angelantonio, Olivier Harari, John Danesh. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies.
Lancet (London, England).
2012 Mar; 379(9822):1205-13. doi:
10.1016/s0140-6736(11)61931-4. [PMID: 22421339] - Sreekanth Racherla, Rohit Arora. Utility of Lp-PLA2 in lipid-lowering therapy.
American journal of therapeutics.
2012 Mar; 19(2):115-20. doi:
10.1097/mjt.0b013e3181e70d32. [PMID: 20634673] - Jean Kyung Paik, Ji Young Kim, Oh Yoen Kim, Yonghee Lee, Tae-Sook Jeong, Gary Sweeney, Yangsoo Jang, Jong Ho Lee. Circulating and PBMC Lp-PLA2 associate differently with oxidative stress and subclinical inflammation in nonobese women (menopausal status).
PloS one.
2012; 7(2):e29675. doi:
10.1371/journal.pone.0029675. [PMID: 22359537] - Mário A C Silva-Neto, Alan B Carneiro, Livia Silva-Cardoso, Georgia C Atella. Lysophosphatidylcholine: A Novel Modulator of Trypanosoma cruzi Transmission.
Journal of parasitology research.
2012; 2012(?):625838. doi:
10.1155/2012/625838. [PMID: 22132309] - Paula Vainio, Laura Lehtinen, Tuomas Mirtti, Mika Hilvo, Tuulikki Seppänen-Laakso, Johannes Virtanen, Anna Sankila, Stig Nordling, Johan Lundin, Antti Rannikko, Matej Orešič, Olli Kallioniemi, Kristiina Iljin. Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins.
Oncotarget.
2011 Dec; 2(12):1176-90. doi:
10.18632/oncotarget.397. [PMID: 22202492] - Alexandros F Tselepis, Manfredi Rizzo, Ioannis A Goudevenos. Therapeutic modulation of lipoprotein-associated phospholipase A2 (Lp-PLA2).
Current pharmaceutical design.
2011 Nov; 17(33):3656-61. doi:
10.2174/138161211798220936. [PMID: 22074435] - Miao-miao Hu, Jie Zhang, Wen-yi Wang, Wen-yu Wu, Yan-ling Ma, Wei-hai Chen, Yi-ping Wang. The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice.
Acta pharmacologica Sinica.
2011 Oct; 32(10):1253-8. doi:
10.1038/aps.2011.127. [PMID: 21970837] - Michelle L O'Donoghue, Eugene Braunwald, Harvey D White, Patrick Serruys, Ph Gabriel Steg, Judith Hochman, Aldo P Maggioni, Christoph Bode, Douglas Weaver, Joel L Johnson, Greg Cicconetti, Mary Ann Lukas, Elizabeth Tarka, Christopher P Cannon. Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome.
American heart journal.
2011 Oct; 162(4):613-619.e1. doi:
10.1016/j.ahj.2011.07.018. [PMID: 21982651] - Isis T Silva, Ana P Q Mello, Nágila R T Damasceno. Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A₂ (Lp-PLA₂): a review.
Lipids in health and disease.
2011 Sep; 10(?):170. doi:
10.1186/1476-511x-10-170. [PMID: 21955667] - M S Ahmed, Jing Zhang Ji, Qing H Meng. Lipoprotein-associated phospholipase A2: how effective as a risk marker of cardiovascular disease and as a therapeutic target?.
Inflammation & allergy drug targets.
2011 Aug; 10(4):236-46. doi:
10.2174/187152811796117771. [PMID: 21539512] - Keane K Lee, Stephen P Fortmann, Ann Varady, Joan M Fair, Alan S Go, Thomas Quertermous, Mark A Hlatky, Carlos Iribarren. Racial variation in lipoprotein-associated phospholipase A₂ in older adults.
BMC cardiovascular disorders.
2011 Jun; 11(?):38. doi:
10.1186/1471-2261-11-38. [PMID: 21714927] - Jeffrey S Berger, Christie M Ballantyne, Michael H Davidson, Joel L Johnson, Elizabeth A Tarka, Denise Lawrence, Trupti Trivedi, Andrew Zalewski, Emile R Mohler. Peripheral artery disease, biomarkers, and darapladib.
American heart journal.
2011 May; 161(5):972-8. doi:
10.1016/j.ahj.2011.01.017. [PMID: 21570531] - Yangsoo Jang, Dawn Waterworth, Jong-Eun Lee, Kijoung Song, Sujin Kim, Hyo-Soo Kim, Kyung Woo Park, Hyun-Jai Cho, Il-Young Oh, Jeong Euy Park, Bok-Soo Lee, Hyo Jeong Ku, Dong-Jik Shin, Jong Ho Lee, Sun Ha Jee, Bok-Ghee Han, Hye-Yoon Jang, Eun-Young Cho, Patrick Vallance, John Whittaker, Lon Cardon, Vincent Mooser. Carriage of the V279F null allele within the gene encoding Lp-PLA₂ is protective from coronary artery disease in South Korean males.
PloS one.
2011 Apr; 6(4):e18208. doi:
10.1371/journal.pone.0018208. [PMID: 21490708] - Ralph A H Stewart, Harvey D White. The role of lipoprotein-associated phospholipase a₂ as a marker and potential therapeutic target in atherosclerosis.
Current atherosclerosis reports.
2011 Apr; 13(2):132-7. doi:
10.1007/s11883-010-0158-8. [PMID: 21207201] - Young-Guk Ko, Byeong-Keuk Kim, Byoung Kwon Lee, Woong Chol Kang, Seung Hyuk Choi, Sang Wook Kim, Jong Ho Lee, Myoungsook Lee, Yasuhiro Honda, Peter J Fitzerald, Won-Heum Shim. Study design and rationale of 'Synergistic effect of combination therapy with cilostazol and ProbUcol on plaque stabilization and lesion REgression (SECURE)' study: a double-blind randomised controlled multicenter clinical trial.
Trials.
2011 Jan; 12(?):10. doi:
10.1186/1745-6215-12-10. [PMID: 21226953] - Michael Liang, Aniket Puri, Gerard Devlin. The vulnerable plaque: the real villain in acute coronary syndromes.
The open cardiovascular medicine journal.
2011; 5(?):123-9. doi:
10.2174/1874192401105010123. [PMID: 21673834] - Wen-yi Wang, Jie Zhang, Wen-yu Wu, Jie Li, Yan-ling Ma, Wei-hai Chen, Hong Yan, Kai Wang, Wen-wei Xu, Jian-hua Shen, Yi-ping Wang. Inhibition of lipoprotein-associated phospholipase A2 ameliorates inflammation and decreases atherosclerotic plaque formation in ApoE-deficient mice.
PloS one.
2011; 6(8):e23425. doi:
10.1371/journal.pone.0023425. [PMID: 21909350] - Harvey White, Claes Held, Ralph Stewart, David Watson, Robert Harrington, Andrzej Budaj, Ph Gabriel Steg, Christopher P Cannon, Susan Krug-Gourley, Janet Wittes, Trupti Trivedi, Elizabeth Tarka, Lars Wallentin. Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease.
American heart journal.
2010 Oct; 160(4):655-61. doi:
10.1016/j.ahj.2010.07.006. [PMID: 20934559] - Marshall A Corson. Darapladib: an emerging therapy for atherosclerosis.
Therapeutic advances in cardiovascular disease.
2010 Aug; 4(4):241-8. doi:
10.1177/1753944710375820. [PMID: 20660537] - Harvey White. Editorial: why inhibition of lipoprotein-associated phospholipase A2 has the potential to improve patient outcomes.
Current opinion in cardiology.
2010 Jul; 25(4):299-301. doi:
10.1097/hco.0b013e32833aaa94. [PMID: 20485161] - Berna Atik, S Claiborne Johnston, Deborah Dean. Association of carotid plaque Lp-PLA(2) with macrophages and Chlamydia pneumoniae infection among patients at risk for stroke.
PloS one.
2010 Jun; 5(6):e11026. doi:
10.1371/journal.pone.0011026. [PMID: 20543948] - Sonia-Athina Karabina, Sarah Gora, Rajai Atout, Ewa Ninio. Extracellular phospholipases in atherosclerosis.
Biochimie.
2010 Jun; 92(6):594-600. doi:
10.1016/j.biochi.2010.02.002. [PMID: 20153800] - Peter P Toth, Peter A McCullough, Michael S Wegner, Kenneth J Colley. Lipoprotein-associated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarker.
Expert review of cardiovascular therapy.
2010 Mar; 8(3):425-38. doi:
10.1586/erc.10.18. [PMID: 20222820] - Lynne T Braun, Michael H Davidson. Lp-PLA2: A new target for statin therapy.
Current atherosclerosis reports.
2010 Jan; 12(1):29-33. doi:
10.1007/s11883-009-0074-y. [PMID: 20425268] - Robert L Wilensky, Colin H Macphee. Lipoprotein-associated phospholipase A(2) and atherosclerosis.
Current opinion in lipidology.
2009 Oct; 20(5):415-20. doi:
10.1097/mol.0b013e3283307c16. [PMID: 19667981] - Robert F Riley, Marshall A Corson. Darapladib, a reversible lipoprotein-associated phospholipase A2 inhibitor, for the oral treatment of atherosclerosis and coronary artery disease.
IDrugs : the investigational drugs journal.
2009 Oct; 12(10):648-55. doi:
". [PMID: 19790016] - Peter A McCullough. Darapladib and atherosclerotic plaque: should lipoprotein-associated phospholipase A2 be a therapeutic target?.
Current atherosclerosis reports.
2009 Sep; 11(5):334-7. doi:
10.1007/s11883-009-0050-6. [PMID: 19664375] - Hector M Garcia-Garcia, Patrick W Serruys. Phospholipase A2 inhibitors.
Current opinion in lipidology.
2009 Aug; 20(4):327-32. doi:
10.1097/mol.0b013e32832dd4c7. [PMID: 19550325] - M T Chhabria, B M Mahajan. Update on patented cholesterol absorption inhibitors.
Expert opinion on therapeutic patents.
2009 Aug; 19(8):1083-107. doi:
10.1517/13543770903036826. [PMID: 19552506] - Robert L Wilensky, Yi Shi, Emile R Mohler, Damir Hamamdzic, Mark E Burgert, Jun Li, Anthony Postle, Robert S Fenning, James G Bollinger, Bryan E Hoffman, Daniel J Pelchovitz, Jisheng Yang, Rosanna C Mirabile, Christine L Webb, LeFeng Zhang, Ping Zhang, Michael H Gelb, Max C Walker, Andrew Zalewski, Colin H Macphee. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development.
Nature medicine.
2008 Oct; 14(10):1059-66. doi:
10.1038/nm.1870. [PMID: 18806801] - Patrick W Serruys, Héctor M García-García, Pawel Buszman, Paul Erne, Stefan Verheye, Michael Aschermann, Henrikus Duckers, Oyvind Bleie, Dariusz Dudek, Hans Erik Bøtker, Clemens von Birgelen, Don D'Amico, Tammy Hutchinson, Andrew Zambanini, Frits Mastik, Gerrit-Anne van Es, Antonius F W van der Steen, D Geoffrey Vince, Peter Ganz, Christian W Hamm, William Wijns, Andrew Zalewski. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque.
Circulation.
2008 Sep; 118(11):1172-82. doi:
10.1161/circulationaha.108.771899. [PMID: 18765397] - Emile R Mohler, Christie M Ballantyne, Michael H Davidson, Markolf Hanefeld, Luis M Ruilope, Joel L Johnson, Andrew Zalewski. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Journal of the American College of Cardiology.
2008 Apr; 51(17):1632-41. doi:
10.1016/j.jacc.2007.11.079. [PMID: 18436114] - L W Tjoelker, C Wilder, C Eberhardt, D M Stafforini, G Dietsch, B Schimpf, S Hooper, H Le Trong, L S Cousens, G A Zimmerman, Y Yamada, T M McIntyre, S M Prescott, P W Gray. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase.
Nature.
1995 Apr; 374(6522):549-53. doi:
10.1038/374549a0. [PMID: 7700381]